🇮🇳·15h agoIndustry
adcock ingram completes delisting from jse natco pharma acquires 35 75 stake
Publisher
N
Natco Pharma
India
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on natcopharma.co.in
Leave the platform to read the original full article on the publisher site.
Source: Natco Pharma
Scope: Industry
Related coverage
More related coverage
Bristol-Myers Squibb News·4h ago
Bristol Myers Squibb Reports First Quarter Financial Results for 2026
Eli Lilly News·4h ago
Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines
Merck & Co. (MSD) News·4h ago
Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical Milestones
Recordati·6h ago